Aktuellt
SENASTE
Redeye briefly comments on Spago’s Q3 2021 report. We judge that the company faces several catalysts in the coming months and quarters that could lead to a share price re-rating. We see a good chance for the SpagoPix trial to conclude soon, followed by a potential licensing deal for further development. Additionally, the company is on track to transition its Tumorad project to clinical development in 2022.
LÄS MER
